Clinical Safety of Combined Targeted and L. Therapy in Oncological Patients

about

Clinical Safety of Combined Targeted and L. Therapy in Oncological Patients

Item

http://www.wikidata.org/entity/Q58760840

description

scientific article published on 06 September 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Clinical Safety of Combined Targeted and L. Therapy in Oncological Patients

@en

Clinical Safety of Combined Targeted and L. Therapy in Oncological Patients

@nl

type

Item

label

Clinical Safety of Combined Targeted and L. Therapy in Oncological Patients

@en

Clinical Safety of Combined Targeted and L. Therapy in Oncological Patients

@nl

prefLabel

Clinical Safety of Combined Targeted and L. Therapy in Oncological Patients

@en

Clinical Safety of Combined Targeted and L. Therapy in Oncological Patients

@nl

P1476

Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients

@en

P2093

Anja Thronicke

http://www.w3.org/2001/XMLSchema#string

Antje Merkle

http://www.w3.org/2001/XMLSchema#string

Harald Matthes

http://www.w3.org/2001/XMLSchema#string

Shiao Li Oei

http://www.w3.org/2001/XMLSchema#string

P2860

Mistletoe therapy in oncology

Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials

Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.

The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).

Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study.

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Targeting angiogenesis with integrative cancer therapies.

Mistletoe in cancer - a systematic review on controlled clinical trials.

Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.

P304

100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/MEDICINES5030100

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Friedemann Schad

P577

2018-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30200590

http://www.w3.org/2001/XMLSchema#string

P932

6164814

http://www.w3.org/2001/XMLSchema#string